These polymorphisms have been found to be associated with postmenopausal breast cancer risk, with significant effect modification by menopausal status where this association was evident only in women with ER- and/or PR-negative breast tumors but not ER- and/or PR-positive tumors [57]. This evidence concerns the gene ESR1 and breast carcinoma.